Fig. 1.
First-phase decline in HCV RNA versus baseline plasma IP-10 concentration. A linear fit of first-phase decline in HCV RNA versus baseline IP-10 concentration shows a positive correlation (all patients, r2 = 0.29 and P = 0.0008). First-phase decline was defined as the reduction in HCV RNA observed 24 h after initiation of danoprevir treatment.